

Stockholm, Sweden
March 17, 2020

Statement by Atlas Antibodies AB on Business Continuity during COVID-19 Outbreak

Dear Customer/Partner:

To assist in minimizing the spread of the Coronavirus disease (COVID-19), Atlas Antibodies has taken necessary measures to protect the health and safety of employees, partners, customers. We are committed to keeping you informed of our efforts to ensure minimal disruption to our supply chain, as well as our commitment to the safety of our employees and our partners and customers. This remains our highest priority, as measures are taken to deal with COVID-19 pandemic.

As a life science company with global customers, we are fully committed to ensuring supply around the world and are actively monitoring our supply chain for potential impacts due to escalation in the outbreak of COVID-19. Our priorities are to ensure the continued supply of our products, and to safeguard the health and wellbeing of all our employees and others.

We have implemented temporary measures to help reduce the risk of infection. These include leveraging digital technology to support working-from-home wherever applicable, as well as cancelling all business travel, off-site meetings and all but essential external visitors to Atlas Antibodies' site. Our guidance is aligned with local government authorities.

As the COVID-19 outbreak continues, Atlas Antibodies continues to monitor the situation closely, establishing protocols and guidelines to minimize the impact whenever possible to our employees, our operations and our supply. We are following guidance outlined by the WHO, CDC and Swedish government authorities, many of which have made hygiene and safety recommendations and implemented transportation restrictions.

Atlas Antibodies have actively assessed the overall supply chain of both our products and key raw material suppliers to mitigate any potential supply disruption. Our business continuity plans include risk mitigation activities in all critical areas, including internal backfill plan for critical staff. We have not experienced any significant disruption to the availability of our products to date due to the outbreak of COVID-19. We continue to monitor our raw materials supply and delivery services, and any identified impact on orders will be communicated directly through our Commercial team.

Thank you for your patience during this challenging time. We will continue to update you as this situation evolves.



John Daicic, CEO
Atlas Antibodies AB

